Tech Company Financing Transactions

Protagonist Therapeutics Funding Round

Canaan Partners, Adage Capital Management and Foresite Capital invested in a $40 million Series C venture round for Protagonist Therapeutics. The financing round was announced on 7/20/2015.

Transaction Overview

Company Name
Protagonist Therapeutics
Announced On
7/20/2015
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series C
Investors

Canaan Partners (Lead Investor) (Julie Papanek)

Adage Capital Management

Foresite Capital

Johnson & Johnson Development Corporation (Asish Xavier)

Lilly Ventures (Armen Shanafelt)

Pharmstandard

RA Capital

Starfish Ventures

Proceeds Purpose
Proceeds from the financing will be used to advance Protagonist's development candidate, PTG-100, into human clinical testing as a potential 'oral targeted therapy' for inflammatory bowel diseases (IBD), as well as to further the development of additional oral peptide drug candidates in the company's product pipeline. PTG-100 is an orally stable peptide therapeutic that works by specifically blocking alpha-4-beta-7 integrin, a clinically validated target for IBD. Protagonist plans to initiate Phase 1 human clinical testing of PTG-100 by the end of 2015, and progress to Phase 1/2 clinical studies in IBD patients during 2016.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
7707 Gateway Blvd. 140
Newark, CA 94560
USA
Phone
(510) 474-0170
Website
www.protagonist-inc.com
Email Address
[email protected]
Overview
Protagonist Therapeutics (NASDAQ: PTGX) is a biotechnology company pursuing the discovery and development of disulfide-rich peptides (DRPs) as well differentiated alternatives to biologics.
Profile
Protagonist Therapeutics LinkedIn Company Profile
Social Media
Protagonist Therapeutics Company Twitter Account
Company News
Protagonist Therapeutics News
Facebook
Protagonist Therapeutics on Facebook
YouTube
Protagonist Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Dinesh Patel
  Dinesh Patel LinkedIn Profile  Dinesh Patel Twitter Account  Dinesh Patel News  Dinesh Patel on Facebook
Chief Financial Officer
Donald Kalkofen
  Donald Kalkofen LinkedIn Profile  Donald Kalkofen Twitter Account  Donald Kalkofen News  Donald Kalkofen on Facebook
Chief Medical Officer
Samuel Saks
  Samuel Saks LinkedIn Profile  Samuel Saks Twitter Account  Samuel Saks News  Samuel Saks on Facebook
Chief Scientific Officer
David Liu
  David Liu LinkedIn Profile  David Liu Twitter Account  David Liu News  David Liu on Facebook
VP - Bus. Development
Suneel Gupta
  Suneel Gupta LinkedIn Profile  Suneel Gupta Twitter Account  Suneel Gupta News  Suneel Gupta on Facebook
VP - Bus. Development
Tracy Woody
  Tracy Woody LinkedIn Profile  Tracy Woody Twitter Account  Tracy Woody News  Tracy Woody on Facebook

 

 

Browse more venture capital transactions:

Prev: 7/20/2015: NanoMersion venture capital transaction
Next: 7/21/2015: Avaxia Biologics venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to report on all VC transactions involving tech companies. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.